In a further sign that marijuana has attained legitimacy on Wall Street, Merrill Lynch has initiated coverage on the sector in recent months – and analysts at the firm are particularly optimistic about the prospects of five cannabis companies, whose stocks they rate as Buy. For these five marijuana stocks – including what could be “an off-the-radar play for investors looking for a marijuana play with lower name recognition” – CLICK HERE.
A recreational boat dealer, a small bank, and a manufacturer of tow trucks and car carriers with “no following on Wall Street whatsoever” are among the five stocks highlighted in today’s article as possible “undiscovered gems”. More specifically, each of these five picks is from the realm of small stocks (with the author noting that “Your odds of finding an undiscovered gem are higher” in this space) and the recipient of scant analyst coverage. For more, CLICK HERE.
Which of the top cannabis stocks listed in the U.S. is the consensus favorite of Wall Street? Today’s article ranks the top “cannabis contenders” (including Canopy Growth, Aurora Cannabis, Tilray and Zynerba Pharmaceuticals) based on analyst ratings and upside potential – and while it comes down to a close race between two cannabis stocks, one stock is ultimately singled out as Wall Street’s favorite to buy. For more, CLICK HERE.
Each of the five stocks highlighted in today’s article is currently trading at less than book value, has earnings, pays a dividend and, the author notes, “these companies are well outside the Facebook/Apple/Netflix/Google arena that presently captivates most of the business media and many investment house analysts.” For these five stocks that may be worthy of further consideration – including an insurance company, a business development company and a Greece-based shipping company – CLICK HERE.
If you’re looking for better returns this year, you may be best to look outside the United States. Today’s article looks at how, with the belief that U.S. equities are overvalued, many Wall Street analysts are looking to Europe, where equities are seen as offering value and economic growth appears robust. The author highlights a number of exchange-traded funds that U.S. investors can use to invest in European markets – and which could be big winners based on price targets. For more, CLICK HERE.
Out of the nearly 5,000 analysts tracked by the website TipRanks, the five who give their top stock picks for 2018 in today’s article have the most profitable track records based on “the average return and success rate of their buy-sell recommendations over the last year.” So which five specific stocks do these top Wall Street minds see outperforming in the coming year, how much upside do they see for them – and why? CLICK HERE.
Donald Trump doesn’t like losers – but investors may be well served by focusing on areas of the stock market that have not gotten swept up in the market surge that followed Trump’s election. The author of today’s article argues that “now is the perfect time to embrace your inner contrarian and look to out-of-favor parts of the stock market that the rest of Wall Street is convinced will get crushed under Trump.” For a look at the contrarian case for emerging markets, U.S. multinationals, drug stocks and utilities – as well as for specific plays the author recommends for each of these sectors – CLICK HERE.
The first weeks of the Trump presidency have been tumultuous to say the least – and as the author of today’s article notes, it “has Wall Street adjusting and readjusting, trying to figure out how the market will move next. But the truth is: No one knows.” In light of this current reality, the author advocates putting money in low-volatility funds – and he highlights three that offer not only safety but also high yields. To find out what these three high-yielding low-volatility ETFs are, CLICK HERE.
“There isn’t a day that goes by on Wall Street when certain stocks trading under $10 a share don’t experience massive spikes higher,” notes the author of today’s article, who proceeds to highlight five stocks currently trading under $10 that are acting technically bullish. To see what these five stocks are – a technology player, a molecular diagnostics player and three biopharmaceutical players – as well as for the technicals and the author’s buying strategies for each, CLICK HERE.
For those worried about high valuations and the prospect of a pullback in the post-election rally, today’s article highlights what the author believes “may be three of the last value plays left on Wall Street right now” to consider as an alternative to chasing growth. To find out what these three stocks are – each of which offers a sustainable dividend yield in the 4% range in addition to bargain pricing – CLICK HERE.